R. Jacob Vogelstein
Founder presso Mind-X Corp.
Profilo
Jacob Vogelstein is the Co-Founder and Managing Partner of Catalio Capital Management, LP.
He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies.
He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
Jacob currently serves on the Boards of Pheast Therapeutics, ManaT Bio, Iambic and Blackrock Neurotech.
Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun-out of T.
Rowe Price, where he focused on making biomedical technology investments.
Earlier in his career, Jacob served on the faculty at Johns Hopkins University, at both the Applied Physics Laboratory and the Whiting School of Engineering.
Jacob has received widespread recognition for his innovative work in biomedical engineering including the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the US Government on science and engineering professionals in the early stages of their careers.
Jacob earned his BSc.
degree in Bio-Electrical Engineering from Brown University and his Ph.D.
degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.
Posizioni attive di R. Jacob Vogelstein
| Società | Posizione | Inizio |
|---|---|---|
Mind-X Corp.
 Mind-X Corp. Packaged SoftwareTechnology Services Mind-X Corp. designs and develops software application. The firm offers MindX. The company was founded by R. Jacob Vogelstein, Julia Brown, and Emily Caporello Bluvas in 2017 and is headquartered in Bethesda, MD. | Founder | 01/01/2017 |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Founder | 01/06/2020 |
| Catalio Access Fund V LLC | Director/Board Member | - |
Cage Pharma, Inc.
 Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cage Pharma, Inc. operates as a developmental stage bio-pharmaceutical company. It focuses on developing anti-cancer drugs. The company was founded on October 24, 2008 by Jean–Francois H. Geschwind and is headquartered in Potomac, MD. | Director/Board Member | 01/12/2017 |
| Catalio Special Opportunities Fund Iii LLC | Director/Board Member | - |
| Catalio Genesis Fund II LLC | Director/Board Member | - |
| Catalio Genesis Fund IV LLC | Director/Board Member | - |
Catalio Capital Management LP (Investment Management)
 Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio Capital Management LP (Investment Management) (Catalio-IM) is the hedge fund management division of Catalio Capital Management LP, a venture capital firm headquartered in New York City. The firm was founded in 2020 by George Petrocheilos and R. Jacob Vogelstein. Catalio-IM serves as an investment manager and provides discretionary investment management services to several privately offered investment funds and vehicles that are generally open to, among others, institutions, pension plans, endowments, high net-worth individuals, financially sophisticated individuals, and other qualified investors. | Chief Executive Officer | 01/01/2020 |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The private company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Director/Board Member | - |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di R. Jacob Vogelstein
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di R. Jacob Vogelstein
| Brown University | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Metabolon, Inc.
 Metabolon, Inc. Packaged SoftwareTechnology Services Metabolon, Inc. operates as a health technology company. It offers precision medicine, clinical diagnostic, and metabolomics services. The firm serves to the pharmaceutical, biotechnology, consumer product industries. The company was founded in 2000 and is headquartered in Morrisville, NC. | Technology Services |
Global Domain Partners LLC
 Global Domain Partners LLC Investment Banks/BrokersFinance Global Domain Partners LLC provides security and trading services. The firm provides managed services to forecasting companies that uses optimization modeling as a predictive tool for worldwide markets, currencies and commodities. The company was founded by David S. Oros and is located in Baltimore, MD. | Finance |
Camden Partners Private Equity
 Camden Partners Private Equity Investment ManagersFinance Camden Partners Private Equity (Camden Partners) is a private equity subsidiary of Camden Partners Holdings LLC founded in 1995 by David Lyle Warnock. The firm is headquartered in Baltimore, Maryland. | Finance |
Aruene Corp.
 Aruene Corp. Medical SpecialtiesHealth Technology Aruene Corp. develops portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine. It offers SpringTMS, a transcranial magnetic stimulation device for the acute treatment of pain associated with migraine headache with aura. The company was founded by Robert E. Fischell and David R. Fischell in 2002 and is headquartered in Baltimore, MD. | Health Technology |
Cage Pharma, Inc.
Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cage Pharma, Inc. operates as a developmental stage bio-pharmaceutical company. It focuses on developing anti-cancer drugs. The company was founded on October 24, 2008 by Jean–Francois H. Geschwind and is headquartered in Potomac, MD. | Health Technology |
Mind-X Corp.
Mind-X Corp. Packaged SoftwareTechnology Services Mind-X Corp. designs and develops software application. The firm offers MindX. The company was founded by R. Jacob Vogelstein, Julia Brown, and Emily Caporello Bluvas in 2017 and is headquartered in Bethesda, MD. | Technology Services |
Gigantum, Inc.
 Gigantum, Inc. Packaged SoftwareTechnology Services Gigantum, Inc. provides computer software. It offers data science, docker, jupyter and python. The company was founded by Tyler J. Whitehouse, Dean Kleissas, Jacob R. Vogelstein, Randal Burns and Joshua Vogelstein and is headquartered in Washington, DC. | Technology Services |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |
Entos, Inc.
 Entos, Inc. Packaged SoftwareTechnology Services Entos, Inc. is a company founded in 2019 and based in an undisclosed location. The American company is focused on disrupting therapeutic discovery with its cutting-edge platform, Orbnet, which combines AI-driven technology and automated synthetic development to rapidly design small-molecule therapeutics. The company's team is comprised of renowned scientists and engineers, including Chemistry Nobel Prize winner Frances Arnold, with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry. The company was founded by Tom Miller and Fred Manby, and Tom Miller has been the CEO since incorporation. | Technology Services |
| Catalio Access Fund V LLC | Finance |
| Catalio Genesis Fund II LLC | Finance |
| Catalio Genesis Fund IV LLC | Finance |
| Catalio Special Opportunities Fund Iii LLC | Finance |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The private company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Health Services |
Catalio Capital Management LP (Investment Management)
Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio Capital Management LP (Investment Management) (Catalio-IM) is the hedge fund management division of Catalio Capital Management LP, a venture capital firm headquartered in New York City. The firm was founded in 2020 by George Petrocheilos and R. Jacob Vogelstein. Catalio-IM serves as an investment manager and provides discretionary investment management services to several privately offered investment funds and vehicles that are generally open to, among others, institutions, pension plans, endowments, high net-worth individuals, financially sophisticated individuals, and other qualified investors. | Finance |
- Borsa valori
- Insiders
- R. Jacob Vogelstein
